In the ‘Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis’ (FLINT) study, obeticholic acid (OCA), an FXR agonist, was shown to improve primary histological outcomes significantly and reduce liver fibrosis in MASH [140]. Here, NR1H4 is linked to Hepatic fibrosis.